{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:49:22Z","timestamp":1793659762088,"version":"4.5.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41379-022-01085-9","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:03:53Z","timestamp":1652400233000},"page":"1227-1235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-6197","authenticated-orcid":false,"given":"Christophe","family":"Bontoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Simonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2498-0376","authenticated-orcid":false,"given":"Ludovic","family":"Lhermitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Touzart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Andrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lenglin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry Jo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Macintyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-5314","authenticated-orcid":false,"given":"Vahid","family":"Asnafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-022-01085-9_bib1","doi-asserted-by":"crossref","unstructured":"Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., le Beau, M. M. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood127, 2391\u20132405 (2016).","DOI":"10.1182\/blood-2016-03-643544"},{"key":"10.1038\/s41379-022-01085-9_bib2","doi-asserted-by":"crossref","unstructured":"Kroeze, E., Loeffen, J. L. C., Poort, V. M. & Meijerink, J. P. P. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv4, 3466\u20133473 (2020).","DOI":"10.1182\/bloodadvances.2020001822"},{"key":"10.1038\/s41379-022-01085-9_bib3","doi-asserted-by":"crossref","unstructured":"van der Zwet, J. C. G., Cordo', V., Cant\u00e9-Barrett, K. & Meijerink, J. P. P. Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients. Adv Biol Regul74, 100647 (2019).","DOI":"10.1016\/j.jbior.2019.100647"},{"key":"10.1038\/s41379-022-01085-9_bib4","doi-asserted-by":"crossref","unstructured":"Burkhardt, B., Zimmermann, M., Oschlies, I., Niggli, F., Mann, G., Parwaresch, R. et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol131, 39\u201349 (2005).","DOI":"10.1111\/j.1365-2141.2005.05735.x"},{"key":"10.1038\/s41379-022-01085-9_bib5","doi-asserted-by":"crossref","unstructured":"Burkhardt, B., Reiter, A., Landmann, E., Lang, P., Lassay, L., Dickerhoff, R. et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol27, 3363\u20133369 (2009).","DOI":"10.1200\/JCO.2008.19.3367"},{"key":"10.1038\/s41379-022-01085-9_bib6","doi-asserted-by":"crossref","unstructured":"Hagedorn, N., Acquaviva, C., Fronkova, E., Von Stackelberg, A., Barth, A., Zur Stadt, U. et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of \u201cisolated\u201d and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood110, 4022\u20134029 (2007).","DOI":"10.1182\/blood-2007-04-082040"},{"key":"10.1038\/s41379-022-01085-9_bib7","doi-asserted-by":"crossref","unstructured":"Basso, K., Mussolin, L., Lettieri, A., Brahmachary, M., Lim, W. K., Califano, A. et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer50, 1063\u20131075 (2011).","DOI":"10.1002\/gcc.20924"},{"key":"10.1038\/s41379-022-01085-9_bib8","doi-asserted-by":"crossref","unstructured":"Bonn, B. R., Huge, A., Rohde, M., Oschlies, I., Klapper, W., Voss, R. et al. Whole exome sequencing hints at a unique mutational profile of paediatric T-cell lymphoblastic lymphoma. Br J Haematol vol. 168 308\u2013313 (2015).","DOI":"10.1111\/bjh.13105"},{"key":"10.1038\/s41379-022-01085-9_bib9","doi-asserted-by":"crossref","unstructured":"Feng, H., Stachura, D. L., White, R. M., Gutierrez, A., Zhang, L., Sanda, T. et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell18, 353\u2013366 (2010).","DOI":"10.1016\/j.ccr.2010.09.009"},{"key":"10.1038\/s41379-022-01085-9_bib10","doi-asserted-by":"crossref","unstructured":"Patel, J. L., Smith, L. M., Anderson, J., Abromowitch, M., Campana, D., Jacobsen, J. et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: A children's oncology group report. Br J Haematol159, 454\u2013461 (2012).","DOI":"10.1111\/bjh.12042"},{"key":"10.1038\/s41379-022-01085-9_bib11","doi-asserted-by":"crossref","unstructured":"Bernard, A., Boumsell, L., Reinherz, E., Nadler, L., Ritz, J., Coppin, H. et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood57, 1105\u20131110 (1981).","DOI":"10.1182\/blood.V57.6.1105.bloodjournal5761105"},{"key":"10.1038\/s41379-022-01085-9_bib12","doi-asserted-by":"crossref","unstructured":"Uyttebroeck, A., Vanhentenrijk, V., Hagemeijer, A., Boeckx, N., Renard, M., Wlodarska, I. et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma48, 1745\u20131754 (2007).","DOI":"10.1080\/10428190701509772"},{"key":"10.1038\/s41379-022-01085-9_bib13","doi-asserted-by":"crossref","unstructured":"Haider, Z., Landfors, M., Golovleva, I., Erlanson, M., Schmiegelow, K., Fl\u00e6gstad, T. et al. DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma. Blood Cancer J10, 45 (2020).","DOI":"10.1038\/s41408-020-0310-9"},{"key":"10.1038\/s41379-022-01085-9_bib14","doi-asserted-by":"crossref","unstructured":"Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J.7, e577 (2017).","DOI":"10.1038\/bcj.2017.53"},{"key":"10.1038\/s41379-022-01085-9_bib15","doi-asserted-by":"crossref","unstructured":"Pillon, M., Piglione, M., Garaventa, A., Conter, V., Giuliano, M., Arcamone, G. et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian association of pediatric hematology and oncology. Pediatr Blood Cancer53, 953\u2013959 (2009).","DOI":"10.1002\/pbc.22162"},{"key":"10.1038\/s41379-022-01085-9_bib16","doi-asserted-by":"crossref","unstructured":"Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L. et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. J Clin Oncol vol. 21 3616\u20133622 (2003).","DOI":"10.1200\/JCO.2003.10.116"},{"key":"10.1038\/s41379-022-01085-9_bib17","doi-asserted-by":"crossref","unstructured":"Sandlund, J. T., Pui, C. H., Zhou, Y., Behm, F. G., Onciu, M., Razzouk, B. I. et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: Results of St Jude NHL13 study. Leukemia23, 1127\u20131130 (2009).","DOI":"10.1038\/leu.2008.400"},{"key":"10.1038\/s41379-022-01085-9_bib18","doi-asserted-by":"crossref","unstructured":"Huguet, F., Chevret, S., Leguay, T., Thomas, X., Boissel, N., Escoffre-Barbe, M. et al. Intensified therapy of acute lymphoblastic leukemia in adults: Report of the randomized GRAALL-2005 clinical trial. J Clin Oncol36, 2514\u20132523 (2018).","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"10.1038\/s41379-022-01085-9_bib19","doi-asserted-by":"crossref","unstructured":"Oudot, C., Auclerc, M. F., Levy, V., Porcher, R., Piguet, C., Perel, Y. et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: The FRALLE 93 study. J Clin Oncol26, 1496\u20131503 (2008).","DOI":"10.1200\/JCO.2007.12.2820"},{"key":"10.1038\/s41379-022-01085-9_bib20","doi-asserted-by":"crossref","unstructured":"Burkhardt, B., Taj, M., Garnier, N., Minard-Colin, V., Hazar, V., Mellgren, K. et al. Treatment and outcome analysis of 639 relapsed non-hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers13, 2075 (2021).","DOI":"10.3390\/cancers13092075"},{"key":"10.1038\/s41379-022-01085-9_bib21","doi-asserted-by":"crossref","unstructured":"Trinquand, A., Tanguy-Schmidt, A., Abdelali, R. Ben, Lambert, J., Beldjord, K., Lenglin\u00e9, E. et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-Cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. J Clin Oncol31, 4333\u20134342 (2013).","DOI":"10.1200\/JCO.2012.48.5292"},{"key":"10.1038\/s41379-022-01085-9_bib22","doi-asserted-by":"crossref","unstructured":"Bond, J., Marchand, T., Touzart, A., Cieslak, A., Trinquand, A., Sutton, L. et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: A group for research in adult acute lymphoblastic leukemia study. Haematologica101, 732\u2013740 (2016).","DOI":"10.3324\/haematol.2015.141218"},{"key":"10.1038\/s41379-022-01085-9_bib23","doi-asserted-by":"crossref","unstructured":"Alcazer, V. StatAid: An R package with a graphical user interface for data analysis. J. Open Source Softw5, 2630 (2020).","DOI":"10.21105\/joss.02630"},{"key":"10.1038\/s41379-022-01085-9_bib24","doi-asserted-by":"crossref","unstructured":"Dadi, S., Le Noir, S., Payet-Bornet, D., Lhermitte, L., Zacarias-Cabeza, J., Bergeron, J. et al. TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL via Interaction with ETS1 and Suppression of TCR\u03b1 Gene Expression. Cancer Cell21, 563\u2013576 (2012).","DOI":"10.1016\/j.ccr.2012.02.013"},{"key":"10.1038\/s41379-022-01085-9_bib25","doi-asserted-by":"crossref","unstructured":"Cav\u00e9, H., Suciu, S., Preudhomme, C., Poppe, B., Robert, A., Uyttebroeck, A. et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies 58881 and 58951. Blood103, 442\u2013450 (2004).","DOI":"10.1182\/blood-2003-05-1495"},{"key":"10.1038\/s41379-022-01085-9_bib26","doi-asserted-by":"crossref","unstructured":"Ballerini, P., Landman-Parker, J., Cayuela, J. M., Asnafi, V., Labopin, M., Gandemer, V. et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3\/HOX11L2 gene expression on outcome. Haematologica93, 1658\u20131665 (2008).","DOI":"10.3324\/haematol.13291"},{"key":"10.1038\/s41379-022-01085-9_bib27","doi-asserted-by":"crossref","unstructured":"Balbach, S. T., Makarova, O., Bonn, B. R., Zimmermann, M., Oschlies, I., Klapper, W. et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia vol. 30 970\u2013973 (2016).","DOI":"10.1038\/leu.2015.203"},{"key":"10.1038\/s41379-022-01085-9_bib28","doi-asserted-by":"crossref","unstructured":"Khanam, T., Sandmann, S., Seggewiss, J., Ruether, C., Zimmermann, M., Norvil, A. B. et al. I Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood137, 2347\u20132359 (2021).","DOI":"10.1182\/blood.2020005381"},{"key":"10.1038\/s41379-022-01085-9_bib29","doi-asserted-by":"crossref","unstructured":"Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood114, 647\u2013650 (2009).","DOI":"10.1182\/blood-2009-02-206722"},{"key":"10.1038\/s41379-022-01085-9_bib30","doi-asserted-by":"crossref","unstructured":"Zuurbier, L., Petricoin, E. F., Vuerhard, M. J., Calvert, V., Kooi, C., Buijs- Gladdines, J. G. C. A. M. et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica97, 1405\u20131413 (2012).","DOI":"10.3324\/haematol.2011.059030"},{"key":"10.1038\/s41379-022-01085-9_bib31","doi-asserted-by":"crossref","unstructured":"Li, Z., Song, Y., Zhang, Y., Li, C., Wang, Y., Xue, W. et al. Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. Haematologica vol. 105 E107\u2013E110 (2020).","DOI":"10.3324\/haematol.2019.220863"},{"key":"10.1038\/s41379-022-01085-9_bib32","doi-asserted-by":"crossref","unstructured":"Fayard, E., Moncayo, G., Hemmings, B. A. & Holl\u00e4nder, G. A. Phosphatidylinositol 3-kinase signaling in thymocytes: The need for stringent control. Sci Signal.3, 1\u201313 (2010).","DOI":"10.1126\/scisignal.3135re5"},{"key":"10.1038\/s41379-022-01085-9_bib33","doi-asserted-by":"crossref","unstructured":"Chen, Y., Hou, Q., Yan, W., J, L., D, C., Z, L. et al. PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells. Oncol Res.19, 563\u2013571 (2011).","DOI":"10.3727\/096504012X13340632812677"},{"key":"10.1038\/s41379-022-01085-9_bib34","doi-asserted-by":"crossref","unstructured":"Matsuoka, T., Yashiro, M., Nishioka, N., Hirakawa, K., Olden, K. & Roberts, J. D. PI3K\/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma. Br J Cancer106, 1535\u20131542 (2012).","DOI":"10.1038\/bjc.2012.107"},{"key":"10.1038\/s41379-022-01085-9_bib35","doi-asserted-by":"crossref","unstructured":"Li, B., Xu, W., Lam, A., Y, W., HF, H., XY, G. et al. S Significance of PI3K\/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget8, 38755\u201338766 (2017).","DOI":"10.18632\/oncotarget.16333"},{"key":"10.1038\/s41379-022-01085-9_bib36","doi-asserted-by":"crossref","unstructured":"Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A. & Martini, M. PI3K in cancer\u2013stroma interactions: bad in seed and ugly in soil. Oncogene2014 33:2433, 3083\u20133090 (2013).","DOI":"10.1038\/onc.2013.265"},{"key":"10.1038\/s41379-022-01085-9_bib37","doi-asserted-by":"crossref","unstructured":"Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S. & Duong, J. et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature558, 540\u2013546 (2021).","DOI":"10.1038\/s41586-018-0217-9"},{"key":"10.1038\/s41379-022-01085-9_bib38","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer. N Engl J Med.380, 1929\u20131940 (2019).","DOI":"10.1056\/NEJMoa1813904"},{"key":"10.1038\/s41379-022-01085-9_bib39","doi-asserted-by":"crossref","unstructured":"Weng, A. P., Ferrando, A. A., Lee, W., Morris IV, J. P., Silverman, L. B., Sanchez- Irizarry, C. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science306, 269\u2013271 (2004).","DOI":"10.1126\/science.1102160"},{"key":"10.1038\/s41379-022-01085-9_bib40","doi-asserted-by":"crossref","unstructured":"Aref, S., el Agdar, M., Salama, O., Zeid, T. A. & Sabry, M. Significance of NOTCH1 mutations detections in T-acute lymphoblastic leukemia patients. Cancer Biomark27, 157\u2013162 (2020).","DOI":"10.3233\/CBM-190967"},{"key":"10.1038\/s41379-022-01085-9_bib41","doi-asserted-by":"crossref","unstructured":"Clappier, E., Collette, S., Grardel, N., Girard, S., Suarez, L., Brunie, G. et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia24, 2023\u20132031 (2010).","DOI":"10.1038\/leu.2010.205"},{"key":"10.1038\/s41379-022-01085-9_bib42","doi-asserted-by":"crossref","unstructured":"Breit, S., Stanulla, M., Flohr, T., Schrappe, M., Ludwig, W. D., Tolle, G. et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood108, 1151\u20131157 (2006).","DOI":"10.1182\/blood-2005-12-4956"},{"key":"10.1038\/s41379-022-01085-9_bib43","doi-asserted-by":"crossref","unstructured":"Bonn, B. R., Rohde, M., Zimmermann, M., Krieger, D., Oschlies, I., Niggli, F. et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood121, 3153\u20133160 (2013).","DOI":"10.1182\/blood-2012-12-474148"},{"key":"10.1038\/s41379-022-01085-9_bib44","doi-asserted-by":"crossref","unstructured":"Lepretre, S., Touzart, A., Vermeulin, T., Picquenot, J. M., Tanguy-Schmidt, A., Salles, G. et al. Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study. J Clin Oncol.34, 572\u2013580 (2016).","DOI":"10.1200\/JCO.2015.61.5385"},{"key":"10.1038\/s41379-022-01085-9_bib45","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, V., Ernst, J., Rinke, J., Winkelmann, N., Beck, J. F., Hochhaus, A. et al. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol142, 1641\u20131650 (2016).","DOI":"10.1007\/s00432-016-2174-8"},{"key":"10.1038\/s41379-022-01085-9_bib46","doi-asserted-by":"crossref","unstructured":"Ntziachristos, P., Tsirigos, A., Vlierberghe, P. Van, Nedjic, J., Trimarchi, T.,Flaherty, M. S. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med18, 296\u2013301 (2012).","DOI":"10.1038\/nm.2651"},{"key":"10.1038\/s41379-022-01085-9_bib47","doi-asserted-by":"crossref","unstructured":"Andrieu, G. P., Kohn, M., Simonin, M., Smith, C., Cieslak, A., Dourthe, M.-E. et al. PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. Blood138, 1855\u20131869 (2021).","DOI":"10.1182\/blood.2020010081"},{"key":"10.1038\/s41379-022-01085-9_bib48","doi-asserted-by":"crossref","unstructured":"Broux, M., Prieto, C., Demeyer, S., Bempt, M. vanden, Alberti-Servera, L., Lodewijckx, I. et al. Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. Blood134, 1323-1336 (2019).","DOI":"10.1182\/blood.2019000015"},{"key":"10.1038\/s41379-022-01085-9_bib49","doi-asserted-by":"crossref","unstructured":"Yuan, S., Wang, X., Hou, S., Guo, T., Lan, Y., Yang, S. et al. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. Leukemia36, 370\u2013382 (2022).","DOI":"10.1038\/s41375-021-01392-1"},{"key":"10.1038\/s41379-022-01085-9_bib50","doi-asserted-by":"crossref","unstructured":"Kurzer, J. H. & Weinberg, O. K. PHF6 mutations in hematologic malignancies. Front Oncol11, 704471 (2021).","DOI":"10.3389\/fonc.2021.704471"},{"key":"10.1038\/s41379-022-01085-9_bib51","doi-asserted-by":"crossref","unstructured":"Liu, Y., Easton, J., Shao, Y., Maciaszek, J., Wang, Z., Wilkinson, M. R. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet49, 1211\u20131218 (2017).","DOI":"10.1038\/ng.3909"},{"key":"10.1038\/s41379-022-01085-9_bib52","doi-asserted-by":"crossref","unstructured":"Zhang, H., Wang, H., Qian, X., Gao, S., Xia, J., Liu, J. et al Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing. BMC Cancer20, 211 (2020).","DOI":"10.1186\/s12885-020-6709-7"},{"key":"10.1038\/s41379-022-01085-9_bib53","doi-asserted-by":"crossref","unstructured":"Stengel, A., Kern, W., Haferlach, T., Schnittger, S., Zenger, M. & Haferlach, C. Comparison of TP53 Alterations in Hematological Malignancies. Blood126, 4819\u20134819 (2015).","DOI":"10.1182\/blood.V126.23.4819.4819"},{"key":"10.1038\/s41379-022-01085-9_bib54","doi-asserted-by":"crossref","unstructured":"Cluzeau, T., Sebert, M., Rahm\u00e9, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I. et al. Eprenetapopt Plus Azacitidine In TP53-mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase Ii Study by the Groupe Francophone des My\u00e9lodysplasies (GFM). J Clin Oncol39, 1575\u20131583 (2021).","DOI":"10.1200\/JCO.20.02342"},{"key":"10.1038\/s41379-022-01085-9_bib55","doi-asserted-by":"crossref","unstructured":"Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A. et al. Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes. J Clin Oncol39, 1584\u20131594 (2021).","DOI":"10.1200\/JCO.20.02341"},{"key":"10.1038\/s41379-022-01085-9_bib56","doi-asserted-by":"crossref","unstructured":"Li, Y., Buijs-Gladdines, J. G. C. A. M., Cant\u00e9-Barrett, K., Stubbs, A. P., Vroegindeweij, E. M., Smits, W. K. et al. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T Cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med13, e1002200 (2016).","DOI":"10.1371\/journal.pmed.1002200"},{"key":"10.1038\/s41379-022-01085-9_bib57","doi-asserted-by":"crossref","unstructured":"Delgado-Martin, C., Meyer, L. K., Huang, B. J., Shimano, K. A., Zinter, M. S., Nguyen, J. v et al. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 2017 31:1231, 2568\u20132576 (2017).","DOI":"10.1038\/leu.2017.136"},{"key":"10.1038\/s41379-022-01085-9_bib58","doi-asserted-by":"crossref","unstructured":"Senkevitch, E., Hixon, J., Andrews, C., Barata, J. T., Li, W. & Durum, S. The JAK inhibitor ruxolitinib is effective in treating T cell acute lymphoblastic leukemia with gain of function mutations in IL-7R alpha. Blood126, 1330\u20131330 (2015).","DOI":"10.1182\/blood.V126.23.1330.1330"},{"key":"10.1038\/s41379-022-01085-9_bib59","doi-asserted-by":"crossref","unstructured":"Cabannes, A., Schmidt, A., Brissot, E., Balsat, M., Maury, S., Isnard, F. et al. The combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse\/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On Behalf of the GRAALL). Blood134, 1339 (2019).","DOI":"10.1182\/blood-2019-130818"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01085-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01085-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01085-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:31:49Z","timestamp":1760229109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222002782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0893395222002782"],"URL":"https:\/\/doi.org\/10.1038\/s41379-022-01085-9","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-022-01085-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}